Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21806036 | 0.92 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL1103931 | 0.92 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL11931619 | 0.92 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL8554764 | 0.87 | SMN1; SMN2 (0.70) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL7295446 | 0.86 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL4349202 | 0.85 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL18732908 | 0.84 | SMN1; SMN2 (0.69) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL23592493 | 0.83 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL1939902 | 0.82 | SMN1; SMN2 (0.79) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL17592981 | 0.82 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9ACYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115591-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LTD (IE) | 2025-04-10 | — | — | US | disclosed |
| US-11981667-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2024-05-14 | — | — | US | disclosed |
| CN-118019727-A | Methods for preparing NLRP3 inhibitors | 豪夫迈·罗氏有限公司 | 2024-05-10 | — | — | CN | disclosed |
| US-20240150291-A1 | PROCESS FOR THE PREPARATION OF NLRP3 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2024-05-09 | — | — | US | disclosed |
| CN-111132974-B | Sulfonamide carboxamide compounds | 英夫拉索姆有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20230037255-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LTD (IE) | 2023-02-02 | — | — | US | disclosed |
| US-11465992-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2022-10-11 | — | — | US | disclosed |
| EP-3978489-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | Inflazome Limited (IE) | 2022-04-06 | — | — | EP | disclosed |
| EP-3661925-B1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LTD (IE) | 2021-11-24 | — | — | EP | disclosed |
| US-20200361895-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-11-19 | — | — | US | disclosed |
| EP-1648871-B1 | PIPERIDINE OR 8-AZA-BICYCLO 3.2.1 OCT-3-YL DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2007-10-17 | — | — | EP | disclosed |
| US-7220735-B2 | Benzimidazolone histamine H3 antagonists | SCHERING CORPORATION (US) | 2007-05-22 | — | — | US | disclosed |
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20060205769-A1 | Piperidine or 8-aza-bicyclo[3.2.1]oct-3-yl derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2006-09-14 | — | — | US | disclosed |
| EP-1648871-A1 | PIPERIDINE OR 8-AZA-BICYCLO 3.2.1 OCT-3-YL DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2006-04-26 | — | — | EP | disclosed |
| US-20050043533-A1 | Process for making alpha-substituted hydroxamic acids | PHARMACIA CORPORATION | 2005-02-24 | — | — | US | disclosed |
| WO-2005007629-A1 | PIPERIDINE OR 8-AZA-BICYCLO[3.2.1]OCT-3-YL DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2005-01-27 | — | — | WO | disclosed |
| WO-2004091549-A2 | PROCESS FOR MAKING ALPHA-SUBSTITUTED HYDROXAMIC ACIDS | PHARMACIA CORPORATION (US) | 2004-10-28 | — | — | WO | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205769-A1 | Piperidine or 8-aza-bicyclo[3.2.1]oct-3-yl derivatives useful as modulators of chemokine receptor activity | CCR5, CCR2, CCR7 | SMN1; SMN2 4437/4885NPC1 1914/4885RAB9A 1283/4885 |
| US-20200361895-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | SMN1; SMN2 2674/4885NPC1 370/4885RAB9A 3489/4885 |
| US-20240150291-A1 | PROCESS FOR THE PREPARATION OF NLRP3 INHIBITORS | NLRP3, NOD1, NLRP1 | SMN1; SMN2 4160/4885NPC1 108/4885RAB9A 3430/4885 |
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | SMN1; SMN2 3394/4885NPC1 837/4885RAB9A 85/4885 |
| US-11981667-B2 | Sulfonamide carboxamide compounds | NLRP3, NOD1, PYCARD | SMN1; SMN2 2759/4885NPC1 483/4885RAB9A 2771/4885 |
| US-20250115591-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | SMN1; SMN2 2436/4885NPC1 422/4885RAB9A 2769/4885 |
| US-20050043533-A1 | Process for making alpha-substituted hydroxamic acids | HAAO, RIMKLA, ASPH | SMN1; SMN2 3577/4885NPC1 2508/4885RAB9A 1758/4885 |
| US-20230037255-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | SMN1; SMN2 2558/4885NPC1 429/4885RAB9A 2792/4885 |
| US-11465992-B2 | Sulfonamide carboxamide compounds | NLRP3, NOD1, PYCARD | SMN1; SMN2 2766/4885NPC1 393/4885RAB9A 3070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.